The Asthma Society of Ireland has this week made a formal submission to the Health Information and Quality Authority (HIQA) as part of the public consultation on a long-term RSV (Respiratory Syncytial Virus) immunisation strategy in Ireland.
Policy & advocacy
January 21, 2026
In our submission, we strongly advocate for broad and equitable access to RSV vaccines for those most vulnerable to severe respiratory illness, including people with asthma, infants, and older adults. This builds on our 2026 Pre-Budget Submission, where we called for the introduction and expansion of RSV immunisation as a key prevention measure.
RSV is a common respiratory virus that can cause serious illness and hospitalisation, particularly among infants, older people, and those with underlying respiratory conditions such as asthma. Viral infections are a major trigger for asthma exacerbations, and preventing RSV can play an important role in supporting better asthma control and reducing pressure on health services.
Our key calls to HIQA and policymakers include:
- Full integration of infant RSV immunisation into the National Immunisation Programme
- A targeted RSV Immunisation Pathfinder Programme for older adults, prioritising high-risk groups such as people with asthma
- Investment in public awareness campaigns to improve understanding of RSV and vaccine uptake among eligible groups
While RSV immunisation is not a complete solution, it represents a vital preventative step that can reduce severe illness, improve quality of life, and help people with asthma stay well for longer.
We will continue to push for prevention-focused policies that protect vulnerable communities and strengthen respiratory health across Ireland.